The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer

Authors: ODwyer M.E.; Druker B.J.

Source: Current Cancer Drug Targets, Volume 1, Number 1, May 2001 , pp. 49-57(9)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.

Keywords: Tyrosine Kinase Inhibitor; myelogenous leukaemia; Ph chromosome; allogeneic stem cell; optimal anti-leukemic effects; myelosuppression; CML blast crisis; Bcr-Abl associated leukemias; chronic myelomonocytic leukemic

Language: English

Document Type: Review article

DOI: 10.2174/1568009013334250

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy